Cerenovus Receives CE Mark for Blood Flow Diverter

August 8, 2018

The Johnson & Johnson medical device company Cerenovus was granted CE Mark approval for the use of its Bravo blood flow diverter in treating complex aneurysms.

The device is approved to treat patients that suffer from intracranial aneurysms by diverting blood flow from the aneurysm site.

The flow diverter promotes healing in patients to reduce rupture risks in the brain, reducing the chance of an aneurysm causing a hemorrhagic stroke.

View today's stories